Clinical Trial Update: IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (IDEA-033) evaluating three months dose finding in knee osteoarthritis, followed by a three-month extension, has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• IDEA-033

Snippet

Sponsor: IDEA AG | Conditions: Osteoarthritis; Knee | Phase 3 | Status: COMPLETED